The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by beta-blockers.
When doxazosin was given to patients with hypertension not adequately controlled by beta-blockade, blood pressure was normalized in 94% of the 34 patients (blood pressure less than or equal to 140/85 mm Hg). This reduction in blood pressure was obtained with doxazosin in combination with metoprolol or oxprenolol at a mean final daily dose of 1.3 mg or pindolol or atenolol at 2.0 mg/day. Exercise-induced increase in systolic and diastolic blood pressure was also lower with combined beta-blocker and doxazosin therapy than with beta-blocker alone. After 12 weeks of treatment, the combination of doxazosin and beta-blocker significantly reduced total serum cholesterol and triglyceride levels. All side effects were mild and only one patient was withdrawn from therapy.
Englert
R G
RG
Clinical Research Pfizer/Mack, Karlsruhe, Gars am Inn, West Germany.
Barlage
U
U
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017292:Doxazosin; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D008055:Lipids; D017292:Doxazosin; D011224:Prazosin